12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 11/16 21:32
BRIEF-Alaunos Therapeutics Reports Q3 2022 Financial Results
Reuters · 11/14 12:50
Alaunos Therapeutics Q3 EPS $(0.04) Beats $(0.08) Estimate, Sales $2.91M Up From $398.00K YoY
Benzinga · 11/14 12:30
Alaunos Therapeutics GAAP EPS of -$0.04 beats by $0.03, revenue of $2.9M
Seekingalpha · 11/14 12:02
Alaunos Therapeutics Reports Third Quarter 2022 Financial Results
Presented early data highlighting first successful objective clinical response using non-viral Sleeping Beauty TCR-T cell therapy in solid tumors at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (CICON)Actively enrolling patients in...
GlobeNewswire · 11/14 12:00
Alaunos Therapeutics Q3 2022 Earnings Preview
Seekingalpha · 11/11 17:33
Notable earnings before Monday's open
Seekingalpha · 11/11 14:23
Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022
HOUSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the third quarter ended September 30, 2022 on Monday, November 14, 2022, before the...
GlobeNewswire · 11/08 13:30
BRIEF-Alaunos Therapeutics To Present Data Highlighting Its Huntr Tcr Discovery Platform
Reuters · 11/07 13:44
Alaunos Therapeutics To Present Data Highlighting Its hunTR TCR Discovery Platform At The Society For Immunotherapy Of Cancer 2022 Annual Meeting
Benzinga · 11/07 13:19
Why Cyclerion Therapeutics Shares Traded Lower By Around 38%; Here Are 70 Biggest Movers From Yesterday
Gainers Green Giant Inc. (NASDAQ: GGE) jumped 161.1% to close at $1.88 after dipping 29% on Wednesday.
Benzinga · 10/07 10:29
Why Revelation Biosciences Shares Are Trading Higher By 29%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 98% to $0.2777. Statera Biopharma was recently granted European patent number EP3206708 titled "Methods And Compositions For The Treatment Of Radiation-Related Disorders."
Benzinga · 10/06 16:41
AngioDynamics, Resources Connection And Some Other Big Stocks Moving Lower On Thursday
U.S. stocks traded mixed, with the Dow Jones dropping more than 85 points on Thursday. Here are some big stocks recording losses in today’s session.
Benzinga · 10/06 15:27
Alaunos wins bullish view at Wells Fargo on promise of cell therapy technology
Wells Fargo analyst James Shin and the team assumed coverage on the clinical-stage biotech Alaunos Therapeutics, Inc. (NASDAQ:<a href="
Seekingalpha · 10/04 16:50
Wells Fargo Assumes Alaunos Therapeutics at Overweight, Announces Price Target of $3
Wells Fargo analyst Nick Abbott assumes Alaunos Therapeutics (NASDAQ:TCRT) with a Overweight rating and announces Price Target of $3.
Benzinga · 10/04 11:48
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Yesterday
Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37.
Benzinga · 10/03 07:24
Ainos, InMed top healthcare gainers; Intercept, Axcella lead losers' pack
Gainers: Ainos (AIMD) +59%. InMed Pharmaceuticals (<a href="https://seekinga...
Seekingalpha · 09/30 14:04
US Stock Futures Down Ahead Of Fed Speakers, Economic Data
Pre-open movers U.S. stock futures traded lower in early pre-market trade on Wednesday after closing mostly lower on Tuesday. The S&amp;P 500 index dropped deeper into a bear market after hitting a fresh 2022 low. The S&amp;P 500 is now down 24.3% from its record level in January, while the Dow is now 21.2% below its record high.
Benzinga · 09/28 09:27
Why Aridis Pharmaceuticals Shares Plunged Around 30%; Here Are 81 Biggest Movers From Yesterday
Benzinga · 09/27 09:15
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 09/26 18:07
Webull provides a variety of real-time TCRT stock news. You can receive the latest news about Alaunos Therapeutics, Inc through multiple platforms. This information may help you make smarter investment decisions.
About TCRT
Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. The Company is engaged in developing adoptive TCR engineered T-cell therapies (TCR-T), designed to treat multiple solid tumor types in large cancer patient populations. The Company is leveraging its cancer mutation hotspot TCR library and its non-viral Sleeping Beauty genetic engineering technology to design and manufacture patient-specific cell therapies that target neoantigens arising from common tumor-related mutations in key oncogenic genes, including KRAS, TP53 and EGFR. Its TCR library consists of ten TCRs targeting six solid tumor indications, including non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers. Using its human neoantigen T cell Receptor (hunTR) discovery engine, it analyzes thousands of single T cells simultaneously using bioinformatics and next generation sequencing. Its pipeline includes Library TCR-T cell therapy and mbIL-15 TCR-T cell therapy.